ABBV — AbbVie Inc.

Wall Street is constructive: 31 Buy vs. 11 Hold and 1 Sell, with an average 12-month price target of $287.08 across 18 analysts versus the 2026-09-13 price of $257.06 — roughly 12% implied upside. The 2026-07-31 Q2 print beat on both lines (revenue $16.99B vs. $16.80B consensus; adjusted EPS $3.65 vs. $3.61) and the shares are up 17.0% over six months and 12.9% over three. The only wobble was a ~2.5% post-earnings dip after FY26 EPS guidance was trimmed to $13.87–$14.07 for $0.14 of Apogee dilution, but that has been fully absorbed — the stock sits within ~4% of its 52-week high while RSI rests at a neutral 51.96, i.e. strength without froth.

Revenue is re-accelerating, not decelerating. YoY growth ran +6.6% in Q2 2025, +9.1% in Q3 2025, +10.0% in Q4 2025, +12.4% in Q1 2026 and +10.2% in Q2 2026, with quarterly revenue climbing from $12.31B (Q1 2024) to $16.99B (Q2 2026). Margins are expanding — gross margin 74.7% in Q2 2026 vs. 71.8% in Q2 2025; GAAP operating margin 37.9% vs. 31.7%. GAAP EPS is the noisy line, and the noise is one-off: $0.099 in Q3 2025 and $0.39 in Q1 2026 versus $2.04 in Q2 2026, plus a -$1.49B operating loss in Q4 2024 (R&D of $6.77B that quarter) — all driven by acquired IPR&D/business-development charges, not by the operating business. The trend that actually matters is mix: Skyrizi ($5.51B, +24.4%) and Rinvoq ($2.53B, +24.5%) combined are now ~$8.0B a quarter against Humira's shrinking $706M (-35.9%), with neuroscience up over 20%. The Humira cliff is now a rounding item, not the story. The one caution: TTM free cash flow of $18.14B is essentially flat (-0.5%) versus the prior TTM $18.24B even though revenue grew 10.4% — cash conversion is not keeping pace with the income statement.

Fairly valued to modestly rich, with the headline numbers misleading in both directions. The trailing P/E of 72.4x is meaningless (TTM GAAP EPS of $3.565 is suppressed by IPR&D charges) and the 5-year average P/E of 54.5x is equally distorted. On the numbers that matter as of 2026-09-13: $257.06 / $13.97 (FY26 guidance midpoint) = 18.4x forward; / $14.05 (next-FY consensus) = 18.3x; PEG 1.06. That is a modest premium to large-cap pharma ex-LLY (~10–16x) but defensible given low-double-digit revenue growth. The richer signal is on sales: P/S of 7.05x versus a 5-year average of 5.29x (~33% premium), and EV/EBITDA of 24.5x. P/B is unusable (negative equity of -$5.94B). Verdict: a full price for a good asset — not a bubble, but no margin of safety either.

The market is paying ~18.4x for FY2026 adjusted EPS of ~$13.97 while revenue compounds ~10% and Skyrizi/Rinvoq compound ~24% — that is a fair-for-growth multiple, not growth-at-any-price. The critical nuance: 'adjusted' EPS excludes genuinely cash business-development costs. IPR&D ran $0.58/share YTD through Q2 2026 and the $10.9B Apogee deal is real cash out the door, so GAAP earnings understate the operating business while adjusted EPS flatters cash economics. The honest anchor is TTM free cash flow of $18.14B on a $454B market cap — a 4.0% FCF yield. If Skyrizi/Rinvoq keep compounding above 20% and Apogee's zumilokibart reads out well, 18x is a fine entry and estimates move up. If immunology share shifts to Lilly's Omvoh or J&J's Tremfya, the multiple compresses toward the mid-teens and the current price looks 10–15% expensive. The 2026-10-30 Q3 print (~$3.85 consensus) is the next estimate-reset trigger.

Constructive but extended. As of 2026-09-13: RSI(14) = 51.96 — dead neutral, no overbought or oversold signal. Price $257.06 versus the 20-day SMA (-0.44%, marginally below), 50-day SMA (+1.03%, marginally above) and 200-day SMA (+12.41%, a solid intact uptrend). The stock is ~3.9% below its 52-week high of $267.47 and 34.8% above its 52-week low of $190.75, up 0.26% over one week, 3.36% over one month, 12.91% over three and 17.04% over six. Read: a steady uptrend pausing just under resistance with momentum reset rather than stretched, which is usually continuation-friendly. Entry implication: buying here is buying strength into resistance with no discount; a pullback to the 50-day (~$254) or into the $240s offers better risk/reward, while a clean break above $267.47 confirms the trend.

• Rates and defensive rotation: ABBV's 0.281 beta, S&P Dividend Aristocrat membership and 2.8% yield (declared $1.73 quarterly dividend, payable November 2026) make it a bond-proxy beneficiary of defensive flows and falling yields — but a sharp rise in long rates would compress the multiple it now commands.
• US drug pricing and policy: IRA Medicare negotiation, most-favored-nation style pricing proposals and any tariff-style pressure on pharmaceuticals all sit over the sector; AbbVie's key franchises will eventually face negotiated pricing.
• Immunology competitive intensity: share battles against Eli Lilly's Omvoh and Johnson & Johnson's Tremfya in IBD/psoriasis determine whether Skyrizi and Rinvoq keep compounding above 20% — the single biggest swing factor in the growth algorithm.
• Sector-wide M&A and IPR&D accounting: bolt-on buying across big pharma creates GAAP-versus-adjusted noise; AbbVie's $10.9B Apogee deal and ongoing IPR&D charges consume real cash and blur trailing earnings screens.
• Long-dated patent cliff: loss of exclusivity for Skyrizi/Rinvoq in the early-to-mid 2030s is outside the 12-month window but is the structural valuation anchor the market will start discounting in the late 2020s.

• Q3 2026 earnings on 2026-10-30 (consensus ~$3.85 EPS) — the key read on Skyrizi/Rinvoq momentum and whether operational growth is outrunning the Apogee dilution.
• Apogee Therapeutics acquisition close (expected Q3 2026, $10.9B) and any zumilokibart Phase 3 data in atopic dermatitis.
• Late-2026 subcutaneous Skyrizi induction approval for Crohn's disease, expanding the IBD label and defending against Tremfya/Omvoh.
• Neuroscience and oncology pipeline readouts, including bretisilocin for depression and the commercial launch of Decnupaz (pivekimab sunirine) for BPDCN — AbbVie's first ADC in blood cancer.
• Annual dividend increase, typically announced with Q3 results — the Dividend Aristocrat streak ($1.73/quarter declared, payable November 2026) is a durable income-investor support.

• Balance sheet: negative stockholders' equity of -$5.94B (6/30/26), $62.48B of long-term debt against $6.57B of cash, and a current ratio of 0.81 leave a thin liquidity cushion and meaningful refinancing exposure.
• Immunology concentration: Skyrizi and Rinvoq now carry the entire growth story (~$8.0B combined in Q2 2026); any share loss to Lilly/J&J or a safety signal would hit an algorithm with no remaining Humira cushion.
• Cash conversion: TTM free cash flow of $18.14B is roughly flat YoY (-0.5%) despite 10.4% revenue growth — the widest gap between 'adjusted EPS' and actual cash generation is the most underappreciated risk here.
• Earnings-quality and GAAP noise: $0.099 diluted EPS in Q3 2025 and $0.39 in Q1 2026 from IPR&D charges; another large charge would spook valuation screens and sentiment even if operationally harmless.
• Valuation risk: at 18.4x forward EPS, 7.05x sales (vs. 5.29x 5-year average) and 24.5x EV/EBITDA, there is little cushion if guidance is trimmed again or immunology growth decelerates below 20%.
• Long-term patent cliff: Skyrizi/Rinvoq loss of exclusivity in the early-to-mid 2030s, with the market likely to begin discounting it well before it arrives.

AbbVie is a well-executed, defensive, cash-generative pharma whose post-Humira growth story is genuinely working — Q2 2026 revenue +10.2% with Skyrizi +24.4% and Rinvoq +24.5% is a clean handoff, not a hope. But as of 2026-09-13 the stock at $257.06 already reflects it: 18.4x forward EPS, 7.05x sales against a 5.29x five-year average, within 4% of 52-week highs, and TTM free cash flow roughly flat YoY despite double-digit revenue growth. This is a good business at a full price — a reasonable long-term income and defensive holding, but not a compelling fresh entry today, and the deterministic score's 'Weak Fundamentals' label is an artifact of IPR&D-distorted GAAP earnings rather than real deterioration.

Forward P/E applied to next-twelve-month adjusted EPS: FY2026 guidance midpoint of $13.97 blended with an FY2027E of ~$15.65 (roughly 12% growth as the $0.14 Apogee dilution rolls off and Skyrizi/Rinvoq keep compounding in the low-20s) gives NTM EPS of ~$14.80, to which I apply an 18.0x multiple — essentially where ABBV already trades (18.3–18.4x), justified versus large-cap pharma's ~10–16x by low-double-digit revenue growth, 13.0% ROIC, a 0.281 beta and Dividend Aristocrat status, but capped because adjusted EPS excludes real cash business-development spend. 18.0 × $14.80 = $267; cross-checked, that implies a 3.85% FCF yield on TTM free cash flow of $18.14B, consistent with a low-beta pharma growing free cash in the low single digits.